In vitro metabolism of KBH-A40, a novel δ-lactam-based histone deacetylase (HDAC) inhibitor, in human liver microsomes and serum

References

• Annunziato AT, Hansen JC. Role of histone acetylation in the assembly and modulation of chromatin structures. Gene Expression 2000; 9: 37–61
   PubMed Web of Science ®Google Scholar
• Baylin SB, Esteller M, Rountree MR, Bachman KE, Schuebel K, Herman JG. Aberrant patterns of DNA methylation, chromatin formation and gene expression in cancer. Human Molecular Genetics 2001; 10: 687–692
   PubMed Web of Science ®Google Scholar
• Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nature Reviews in Drug Discovery 2006; 5: 769–784
   PubMed Web of Science ®Google Scholar
• Du L, Musson DG, Wang AQ. High turbulence liquid chromatography online extraction and tandem mass spectrometry for the simultaneous determination of suberoylanilide hydroxamic acid and its two metabolites in human serum. Rapid Communications in Mass Spectrometry 2005; 19: 1779–1787
   PubMed Web of Science ®Google Scholar
• Elaut G, Torok G, Vinken M, Laus G, Papeleu P, Tourwe D, Rogiers V. Major phase I biotransformation pathways of Trichostatin A in rat hepatocytes and in rat and human liver microsomes. Drug Metabolism and Disposition 2002; 30: 1320–1328
   PubMed Web of Science ®Google Scholar
• Ferron GM, Jusko WJ. Species differences in sirolimus stability in humans, rabbits, and rats. Drug Metabolism and Disposition 1998; 26: 83–84
   PubMed Web of Science ®Google Scholar
• Garber K. HDAC inhibitors overcome first hurdle. Nature Biotechnology 2007; 25: 17–19
   PubMed Web of Science ®Google Scholar
• Hakala KS, Kostiainen R, Ketola RA. Feasibility of different mass spectrometric techniques and programs for automated metabolite profiling of tramadol in human urine. Rapid Communications in Mass Spectrometry 2006; 20: 2081–2090
   PubMed Web of Science ®Google Scholar
• Imai T. Human carboxylesterase isozymes: catalytic properties and rational drug design. Drug Metabolism and Pharmacokinetics 2006; 21: 173–185
   PubMed Web of Science ®Google Scholar
• Jenuwein T, Allis CD. Translating the histone code. Science 2001; 293: 1074–1080
   PubMed Web of Science ®Google Scholar
• Kim HM, Lee K, Park BW, Ryu DK, Kim K, Lee CW, Park S-K, Han JW, Lee HY, Lee HY, et al. Synthesis, enzymatic inhibition, and cancer cell growth inhibition of novel δ-lactam-based histone deacetylase (HDAC) inhibitors. Bioorganic and Medicinal Chemistry Letters 2006; 16: 4068–4070
   PubMed Web of Science ®Google Scholar
• Kim HM, Ryu DK, Choi Y, Park BW, Lee K, Han SB, Lee CW, Kang M-R, Kang JS, Boovanahalli SK, et al. Structure–activity relationship studies of a series of novel δ-lactam-based histone deacetylase inhibitors. Journal of Medicinal Chemistry 2007; 50: 2737–2741
   PubMed Web of Science ®Google Scholar
• Levsen K, Schiebel H-M, Behnke B, Dotzer R, Dreher W, Elend M, Thiele H. Structure elucidation of phase II metabolites by tandem mass spectrometry: an overview. Journal of Chromatography A 2005; 1067: 55–72
   PubMed Web of Science ®Google Scholar
• Li AC, Gohdes MA, Shou WZ. ‘N-in-one’ strategy for metabolite identification using a liquid chromatography/hybrid triple quadrupole linear ion trap instrument using multiple dependent product ion scans triggered with full mass scan. Rapid Communications in Mass Spectrometry 2007; 21: 1421–1430
   PubMed Web of Science ®Google Scholar
• Li B, Sedlacek M, Manoharan I, Boopathy R, Duysen E, Masson P, Lockridge O. Butyrylcholinesterase, paraoxonase, and albumin esterase, but not carboxylesterase, are present in human plasma. Biochemical Pharmacology 2005; 70: 1673–1684
   PubMed Web of Science ®Google Scholar
• Liederer BM, Borchardt RT. Enzymes involved in the bioconversion of ester-based prodrugs. Journal of Pharmaceutical Sciences 2006; 95: 1177–1195
   PubMed Web of Science ®Google Scholar
• Marks PA, Breslow R. Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug. Nature Biotechnology 2007; 25: 84–90
   PubMed Web of Science ®Google Scholar
• Obach RS, Baxer JG, Liston TE, Silber BM, Jones BC, MacIntyre F, Rance DJ, Wastall P. The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data. Journal of Pharmacology and Experimental Therapeutics 1997; 283: 46–58
   PubMed Web of Science ®Google Scholar
• Pang KS, Rowland M. Hepatic clearance of drugs. I. Theoretical considerations of a ‘well-stirred’ model and a ‘parallel tube’ model: influence of hepatic blood flow, plasma and blood cell binding, and the hepatocellular enzymatic activity on hepatic drug clearance. Journal of Pharmacokineitics and Biopharmaceutics 1977; 5: 625–653
   PubMedGoogle Scholar
• Peng SX, Strojnowski MJ, Hu JK, Smith BJ, Eichhold TH, Wehmeyer KR, Pikul S, Almstead NG. Gas chromatographic-mass spectrometric analysis of hydroxylamine for monitoring the metabolic hydrolysis of metalloprotease inhibitors in rat and human liver microsomes. Journal of Chromatography. B: Biomedical Sciences and Applications 1999; 724: 181–187
   PubMed Web of Science ®Google Scholar
• Summers JB, Gunn BP, Mazdiyasni H, Goetze AM, Young PR, Bouska JB, Dyer RD, Brooks DW, Carter GW. In vivo characterization of hydroxamic acid inhibitors of 5-lipoxygenase 1987; 30: 2121–2126
   Google Scholar
• Food US and Drug Administration (USFDA). FDA labeling information 2006, (available at: http://www.fda.gov/cder/foi/label/2006/021991lbl.pdf)
   Google Scholar
• Wu J, Grunstein M. 25 years after the nucleosome model: chromatin modifications. Trends in Biochemical Sciences 2000; 25: 619–623
   PubMed Web of Science ®Google Scholar
• Yoo CB, Jones PA. Epigenetic therapy of cancer: past, present and future. Nature Reviews in Drug Discovery 2006; 5: 37–50
   PubMed Web of Science ®Google Scholar
• Zhang Y, Reinberg D. Transcription regulation by histone methylation: interplay between different covalent modifications of the core histone tails. Genes and Development 2001; 15: 2343–2360
   PubMed Web of Science ®Google Scholar